Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma.
Nomogram
Postoperative morbidity
Retroperitoneal sarcoma
Surgery
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
23 Feb 2023
23 Feb 2023
Historique:
received:
01
07
2022
accepted:
17
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Surgery is the cornerstone of the treatment for primary retroperitoneal sarcoma (RPS). The purpose of this study was to establish a nomogram predictive model for predicting postoperative morbidity in primary RPS. Clinicopathological data of patients who underwent radical resection from 2009 to 2021 were retrospectively analyzed. Risk factor analysis was performed using a logistic regression model, and modeling variables were selected based on Akaike Information Criterion. The nomogram prediction model was built on the basis of a binary logistic regression model and internally validated by calibration curves and concordance index. A total of 319 patients were enrolled, including 162 males (50.8%). 22.9% (n = 73) were over 65 years of age, and 70.2% (n = 224) had tumors larger than 10 cm. The most common histologic subtypes were well-differentiated liposarcoma (38.2%), dedifferentiated liposarcoma (25.1%) and leiomyosarcoma (7.8%). According to the Clavien-Dindo Classification, 96 (31.1%) and 31 (11.6%) patients had grade I-II complications and grade III-V complications, respectively. Age, tumor burden, location, operative time, number of combined organ resections, weighted resected organ score, estimated blood loss and packed RBC transfusion was used to construct the nomogram, and the concordance index of which was 0.795 (95% CI 0.746-0.844). and the calibration curve indicated a high agreement between predicted and actual rates. Nomogram, a visual predictive tool that integrates multiple clinicopathological factors, can help physicians screen RPS patients at high risk for postoperative complications and provide a basis for early intervention.
Sections du résumé
BACKGROUND
BACKGROUND
Surgery is the cornerstone of the treatment for primary retroperitoneal sarcoma (RPS). The purpose of this study was to establish a nomogram predictive model for predicting postoperative morbidity in primary RPS.
METHODS
METHODS
Clinicopathological data of patients who underwent radical resection from 2009 to 2021 were retrospectively analyzed. Risk factor analysis was performed using a logistic regression model, and modeling variables were selected based on Akaike Information Criterion. The nomogram prediction model was built on the basis of a binary logistic regression model and internally validated by calibration curves and concordance index.
RESULTS
RESULTS
A total of 319 patients were enrolled, including 162 males (50.8%). 22.9% (n = 73) were over 65 years of age, and 70.2% (n = 224) had tumors larger than 10 cm. The most common histologic subtypes were well-differentiated liposarcoma (38.2%), dedifferentiated liposarcoma (25.1%) and leiomyosarcoma (7.8%). According to the Clavien-Dindo Classification, 96 (31.1%) and 31 (11.6%) patients had grade I-II complications and grade III-V complications, respectively. Age, tumor burden, location, operative time, number of combined organ resections, weighted resected organ score, estimated blood loss and packed RBC transfusion was used to construct the nomogram, and the concordance index of which was 0.795 (95% CI 0.746-0.844). and the calibration curve indicated a high agreement between predicted and actual rates.
CONCLUSIONS
CONCLUSIONS
Nomogram, a visual predictive tool that integrates multiple clinicopathological factors, can help physicians screen RPS patients at high risk for postoperative complications and provide a basis for early intervention.
Identifiants
pubmed: 36814201
doi: 10.1186/s12893-023-01941-8
pii: 10.1186/s12893-023-01941-8
pmc: PMC9948406
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Informations de copyright
© 2023. The Author(s).
Références
J Surg Oncol. 2019 Sep;120(4):753-760
pubmed: 31355444
Ann Surg Oncol. 2012 Sep;19(9):2981-91
pubmed: 22476756
Eur J Surg Oncol. 2014 Aug;40(8):909-16
pubmed: 24768445
Arch Surg. 1996 Nov;131(11):1165-71; discussion 1171-2
pubmed: 8911256
Ann Surg. 2018 May;267(5):959-964
pubmed: 28394870
Ann Surg. 2016 May;263(5):1002-9
pubmed: 26727100
J Clin Oncol. 2009 Jan 1;27(1):31-7
pubmed: 19047280
Ann Surg Oncol. 2021 Nov;28(12):7873-7888
pubmed: 33852100
Arch Surg. 2001 Apr;136(4):405-11
pubmed: 11296110
Ann Surg. 2011 Apr;253(4):798-810
pubmed: 21475023
Ann Surg Oncol. 2010 Jun;17(6):1507-14
pubmed: 20393803
Ann Surg Oncol. 2018 Aug;25(8):2201-2208
pubmed: 29797115
Cancer. 2010 May 15;116(10):2429-36
pubmed: 20209615
Ann Surg Oncol. 2021 Nov;28(12):7939-7949
pubmed: 33978886
J Clin Oncol. 2013 May 1;31(13):1649-55
pubmed: 23530096
Ann Oncol. 2010 Feb;21(2):397-402
pubmed: 19622598
Front Surg. 2022 Mar 28;9:833296
pubmed: 35419405
Anesthesiology. 2021 Nov 1;135(5):904-919
pubmed: 34491303
Pathologica. 2021 Apr;113(2):70-84
pubmed: 33179614
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542